Refine
Year of publication
Document Type
- Preprint (681)
- Article (609)
- Working Paper (5)
- Book (2)
- Review (1)
Has Fulltext
- yes (1298)
Is part of the Bibliography
- no (1298)
Keywords
- Heavy Ion Experiments (20)
- SARS-CoV-2 (12)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- prostate cancer (6)
- COVID-19 (5)
- COVID19-NMR (5)
- radical prostatectomy (5)
- ALICE experiment (4)
- Atmospheric chemistry (4)
- Collective Flow (4)
- Genetics (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- Solution NMR spectroscopy (4)
- Solution NMR-spectroscopy (4)
- 5′-UTR (3)
- ALICE (3)
- Covid19-NMR (3)
- Heavy Ions (3)
- Immunology (3)
- Jets and Jet Substructure (3)
- Non-structural protein (3)
- Oncology (3)
- Pandemic (3)
- Seizure (3)
- chemotherapy (3)
- immunohistochemistry (3)
- pp collisions (3)
- systematic biopsy (3)
- ADHD (2)
- Beauty production (2)
- Bipolar disorder (2)
- Charm physics (2)
- Cochlear implant (2)
- Corona (2)
- Depression (2)
- Diagnosis (2)
- Digitalisierung (2)
- Digitization (2)
- EWSR1 (2)
- Epileptischer Anfall (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- FFLU (2)
- Fahrradmitnahme (2)
- Fahrradverleihsysteme (2)
- Gene fusion (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Liver transplantation (2)
- NMR spectroscopy (2)
- PD-L1 (2)
- PSA (2)
- Pandemie (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Protein drugability (2)
- Psychiatric disorders (2)
- QCD (2)
- RNA (2)
- SARS-CoV‑2 (2)
- Single electrons (2)
- Status epilepticus (2)
- Survival analysis (2)
- concordance (2)
- drug resistance (2)
- epidemiology (2)
- fMRI (2)
- fusion biopsy (2)
- immunotherapy (2)
- lung cancer (2)
- nutlin-3 (2)
- p53 (2)
- survival (2)
- targeted therapy (2)
- 19F (1)
- 3Cs technology (1)
- 5'-UTR (1)
- 5_SL4 (1)
- 900 GeV (1)
- ABCB1 (1)
- ABCC1 (1)
- ACLF (1)
- AKI (1)
- AKT (1)
- ALICE detector (1)
- ASAP (1)
- Acanthocephalan parasites (1)
- Active middle ear implants (1)
- Acute HIV infection (1)
- Adults (1)
- Aedes aegypti (1)
- Agoraphobia (1)
- Amino acid analysis (1)
- Animal model (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Antifungal agents (1)
- Aortic valve replacement (1)
- Artificial Intelligence (1)
- Aspergillosis (1)
- Atmospheric science (1)
- Auditory system (1)
- Awareness campaign (1)
- Ayurveda (1)
- B cell malignancies (1)
- B cell receptor (1)
- BCOR (1)
- BCORL1 (1)
- BEACOPP (1)
- BI1361849 (1)
- BMI (1)
- BPH (1)
- BPO (1)
- BPTF (1)
- Behavior (1)
- Bike and Ride / Fahrrad-Abstellanlagen (1)
- Bilateral cochlear implant (1)
- Biodiversity (1)
- Biodiversity Data (1)
- Biogeochemistry (1)
- Biological heart valves (1)
- Biological markers (1)
- Biomarker (1)
- Biomarkers (1)
- Biomonitoring (1)
- Biophysical models (1)
- Bioprosthesis (1)
- Bone conduction devices (1)
- Bone tumor (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Brain (1)
- Brain tumor (1)
- Built environment (1)
- Business strategy in drug development (1)
- CD47 (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- CLOUD experiment (1)
- COMT (1)
- COVID (1)
- CRPC (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CTLA-4 (1)
- CV9202 (1)
- Calcium signalling (1)
- Cancer (1)
- Cancer check up (1)
- Cancer genomics (1)
- Cancer treatment (1)
- Cardiac surgery (1)
- Carotid injury (1)
- Cell membranes (1)
- Centrality Class (1)
- Centrality Selection (1)
- Chemical composition (1)
- Chemokine CCL2 (1)
- Chemokines (1)
- Child abuse (1)
- Climate change (1)
- Climate-change impacts (1)
- Clinical Trials and Observations (1)
- Clinical genetics (1)
- Clinical practice guidelines (1)
- Clinical trial (1)
- Clinical variation (1)
- Collective Flow, (1)
- Combo® DTS (1)
- Compact city (1)
- Comparison with QCD (1)
- Complex decongestive therapy (1)
- Complication (1)
- Complications (1)
- Computed axial tomography (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computer-aided drug design (1)
- Congenital anomalies (1)
- Consensus statement (1)
- Conservation (1)
- Conservation biology (1)
- Course (1)
- Course evaluation (1)
- Covid19-nmr (1)
- Crispr/Cas (1)
- Culex pipiens (1)
- Cycle streets (1)
- DNA sequence analysis (1)
- DNA-PAINT (1)
- DUBs (1)
- Decision Making und Risk (1)
- Demolition emissions (1)
- Design functions (1)
- Diagnostic markers (1)
- Dikerogammarus villosus (1)
- Dimerization domain (1)
- Direct reactions (1)
- Distance learning (1)
- Distanzunterricht (1)
- Doxorubicin (1)
- Drug screens (1)
- Drug therapy (1)
- D’Amico classification (1)
- EGFR (1)
- EP300 (1)
- Ecotoxicology (1)
- Elderly (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Embryos (1)
- Environment perception (1)
- Environmental Chemistry (1)
- Environmental impact (1)
- Epilepsy (1)
- Eurasian Curlew (1)
- Europe (1)
- Everolimus (1)
- Extended donor criteria (1)
- FBS (1)
- FGFR (1)
- FOXO1 (1)
- Fahrrad & ÖV (1)
- Fahrradabstellanalgen (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Financial Markets (1)
- Forschung (1)
- Frailty (1)
- Freshwater invertebrates (1)
- Functional outcomes (1)
- GPS collar (1)
- Gene expression (1)
- Gene regulation (1)
- General practitioners (1)
- Gleason Score (1)
- Gleason score (1)
- Gleason upgrading (1)
- Global positioning system (1)
- Global warming (1)
- Graft function (1)
- Graft survival (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HBT (1)
- HIV (1)
- HNO (1)
- HOLEP (1)
- HSP (hereditary spastic paraplegia) (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Head bandage (1)
- Health care workers (1)
- Health policy (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hematologic malignancies (1)
- Hematology (1)
- Hepatocellular carcinoma (1)
- Herbaria (1)
- HoLEP (1)
- Holmium laser enucleation (1)
- Hypertension (1)
- Hypofractionated radiotherapy (1)
- IAP (1)
- IFN (1)
- IHC (1)
- IPSS (1)
- Imaging genetics (1)
- Immune suppression (1)
- Immunogenetics (1)
- Immunomonitoring (1)
- Incidental prostate cancer (1)
- Inclusive spectra (1)
- Inflammation (1)
- Insurance (1)
- Integrated urban planning (1)
- Integrierte Stadtentwicklung (1)
- Integrierte kommunale Strategien (1)
- Intensity interferometry (1)
- Intermodalität (1)
- Invariant Mass Distribution (1)
- Invasive candidiasis (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- KDIGO (1)
- KLHL11 (1)
- Kidney (1)
- Kompakte Stadt (1)
- Lafora disease (1)
- Lee type, functional outcome (1)
- Lehre (1)
- Lehrveranstaltungsevaluation (1)
- Leukemias (1)
- Library screening (1)
- Lipedema (1)
- Liposuction (1)
- Literature review (1)
- Liver diseases (1)
- Locomotion (1)
- Luciferase (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- MDM2 (1)
- MN1 (1)
- MR-proADM (1)
- Machine learning (1)
- Macrodomain (1)
- Macrozoobenthos (1)
- Magnet dislocation (1)
- Magnetic resonance imaging (1)
- Marginal grafts (1)
- Marketing & Kommunikation (1)
- Material budget (1)
- Medical education (1)
- Medical history (1)
- Medizinstudium (1)
- Mental health and psychiatry (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Methodenstudie (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mixed hearing loss (1)
- Mobility design (1)
- Mobilität (1)
- Mobilität in Deutschland (1)
- Mobilitätskennziffern (1)
- Mobilitätspanel (1)
- Molecular subtypes (1)
- Monte Carlo (1)
- Mortality (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Mutation databases (1)
- Mycoses (1)
- Myeloid Neoplasia (1)
- N471D strumpellin knock-in mice (1)
- NADPH oxidase (1)
- NPSR1 (1)
- NURF (1)
- NVBP (1)
- Nachhaltige Stadtentwicklung (1)
- Nephrons (1)
- Neural network (1)
- Neuroepithelial (1)
- Neuroepithelial tumor (1)
- Neurooncology (1)
- Neuroscience (1)
- Nivolumab (1)
- Non-motorised travel (1)
- Non-small cell lung cancer (1)
- Non-small-cell lung cancer (1)
- Non–small-cell lung cancer (1)
- Nox4 (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleic acid-binding domain (1)
- Nucleocapsid (1)
- Nucleon induced nuclear reactions (1)
- Numenius arquata (1)
- OD approach (1)
- OR time (1)
- ORL (1)
- ORP (1)
- Observational study (1)
- Oldest-old (1)
- Online Survey (1)
- Organ rinse (1)
- Organ shortage (1)
- Organic micropollutants (1)
- Otorhinolaryngological (1)
- Otorhinolaryngology (1)
- Outcome (1)
- Overall survival (1)
- Oxygen (1)
- PAD-test (1)
- PATZ1 (1)
- PCR (1)
- PCV (1)
- PD-1 (1)
- PLAGL1 (1)
- PM10 (1)
- PSA screening (1)
- PSA-Screening (1)
- PYTHIA (1)
- Panic disorder (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Pediatric (1)
- Personenmobilität (1)
- Phase 3 (1)
- Phosphorylation (1)
- Post-traumatic stress disorder (1)
- Preventive medicine (1)
- Production Cross Section (1)
- Prognostic markers (1)
- Properties of Hadrons (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Prostate cancer (1)
- Prostatic neoplasms (1)
- Protein druggability (1)
- Proton–proton (1)
- Prävention (1)
- Psychological and psychosocial issues (1)
- Psychology (1)
- Quality of life (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- RARP (1)
- RITA (1)
- RNA genome (1)
- Rabbit (1)
- Radiation exposure (1)
- Radical nephrectomy (1)
- Radical prostatectomy (1)
- Radiofrequency ablation (1)
- Randomisation (1)
- Rapid diagnostic test (1)
- Rapidity Range (1)
- Raumstruktur (1)
- Reactive oxygen species (1)
- Real-world data (1)
- Region Rhein-Main (1)
- Registry (1)
- Rehabilitation (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Renal cancer (1)
- Renal system (1)
- Research (1)
- Research Infrastructure (1)
- Research funding (1)
- Residency (1)
- Resolution Parameter (1)
- Restenosis (1)
- Rhabdomyoma (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SAVI (1)
- SIRPalpha (1)
- SL1 (1)
- SL5a (1)
- SL5b (1)
- SL5b + c (1)
- SL5c (1)
- SMAD (1)
- SOFA (1)
- SPG8 (1)
- STING (1)
- Semantics (1)
- Sepsis (1)
- Septic shock (1)
- Sequential (1)
- Seroconverter (1)
- Shared space (1)
- Shell model (1)
- Simultaneous (1)
- Single muons (1)
- Single-cell RNA sequencing (1)
- Size distribution (1)
- Small molecules (1)
- Small-cell lung cancer (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Stadtplanung (1)
- Stechmückenfalle (1)
- Stegomyia aegypti (1)
- Streams (1)
- Street design (1)
- Structural protein (1)
- Sublethal effects (1)
- Supratentorial (1)
- Surgery (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Sustainable urban development (1)
- Systematic Uncertainty (1)
- TGFβ (1)
- TR (1)
- TUR-P (1)
- Tacrolimus (1)
- Taxonomy (1)
- Teaching (1)
- Technical data (1)
- Temperature preference (1)
- Thermodynamics (1)
- Time Projection Chamber (1)
- Tools and ressources (1)
- Total operating room time (1)
- Tracking (1)
- Traditional Indian Medicine (1)
- Transcriptome analysis (1)
- Transition radiation detector (1)
- Transportation planning (1)
- Transurethral resection of the prostate (1)
- Transverse momentum (1)
- Travel behaviour (1)
- Treatment (1)
- Trigger (1)
- Tumor heterogeneity (1)
- Tumor therapy (1)
- Tumour biomarkers (1)
- Ultrafine particles (1)
- University hospitals (1)
- Universitätskliniken (1)
- Upper Rhine Valley (1)
- Urban aerosol (1)
- Urban planning (1)
- Urban space (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Ursus arctos (1)
- VX-2 (1)
- Vector Boson Production (1)
- Verkehr (1)
- Verkehrsplanung (1)
- Vesicles (1)
- Volmer–Weber growth (1)
- Vorsorgeuntersuchung (1)
- WASH complex subunit 5 (1)
- Weiterbildung (1)
- Westphal-Paradigm (1)
- X-ray powder diffraction (1)
- Xenon-based gas mixture (1)
- YM155 (1)
- accessory proteins (1)
- accident (1)
- activity sensors (1)
- acute myeloid leukemia (1)
- acute-on-chronic liver failure (1)
- adult (1)
- aerosol formation (1)
- aerosols (1)
- aggression (1)
- anti-EGFR therapy (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- antiviral therapy (1)
- arthritis (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- atypical EGFR mutations (1)
- bicycle use (1)
- bioactivity testing (1)
- biogeographic legaciese (1)
- biomarker (1)
- biopsy (1)
- biopsy naïve (1)
- blood loss (1)
- brown bear (1)
- car use reduction (1)
- castration resistance (1)
- catheter removal (1)
- cell biology (1)
- cell lines (1)
- cell-free protein synthesis (1)
- cerebrospinal fluid (1)
- chemorefractory metastatic colorectal cancer (1)
- chemoresistance (1)
- cholangiocarcinoma (1)
- chronic total occlusion (1)
- cirrhosis (1)
- clinical practice (1)
- clinical trial (1)
- clinical trials (1)
- cluttering (1)
- complementary medicine (1)
- complexity (1)
- complications (1)
- consensus (1)
- coronavirus (1)
- correlation (1)
- cycle streets (1)
- cytotoxic T cells (1)
- dE/dx (1)
- data management (1)
- data quality (1)
- death rates (1)
- deferred treatment (1)
- delayed treatment (1)
- denisovite (1)
- detector (1)
- diffuse low-grade glioma (1)
- diffusion-weighted magnetic resonance imaging (1)
- digitale Vernetzung (1)
- disease prevalence (1)
- disorder (1)
- downgrading (1)
- early continence (1)
- easyPACId (1)
- ectosomes (1)
- electroencephalography (EEG) (1)
- electron crystallography (1)
- electron diffraction tomography (1)
- electronic diaries (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- epilepsy (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- fibrous materials (1)
- fluorine (1)
- forest classification (1)
- forest functional similarity (1)
- fragment screening (1)
- fragment-based screening (1)
- framework-structured solids (1)
- gRNA library (1)
- gene therapy (1)
- genetics (1)
- genetics and genomics (1)
- genome-wide (1)
- guidelines (1)
- haemophilia treatment (1)
- head-and-neck cancer (1)
- heavy ion experiments (1)
- histological outcomes (1)
- histopathological growth pattern (1)
- human (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- infection (1)
- injury (1)
- inorganic materials (1)
- integrative medicine (1)
- interaction effect (1)
- interim positron emissiontomography (1)
- interoperability (1)
- interstitial lung disease (1)
- intrinsically disordered region (1)
- inverse stage migration (1)
- irritable bowel syndrome (1)
- juvenile myoclonic epilepsy (1)
- layer-by-layer (LbL) (1)
- level-specific model fit (1)
- likelihood ratio test (1)
- liver (1)
- liver metastasis (1)
- liver transplantation (1)
- lockdown (1)
- loss-of-function (1)
- low-dose imaging (1)
- mRNA active cancer immunotherapy (1)
- mTOR (1)
- mTOR inhibitor (1)
- magnetic resonance imaging (1)
- maternal care (1)
- mechanical ventilation (1)
- medical risk factors (1)
- medulloblastoma (1)
- metal–organic frameworks (1)
- metastasis (1)
- metastatic prostate cancer (1)
- microparticles (1)
- microsatellite instability (1)
- microvesicles (1)
- minerals (1)
- minimal information requirements (1)
- modularity (1)
- morbidity (1)
- mortality (1)
- mosquito trap (1)
- mpMRI (1)
- multicenter study (1)
- multilevel structural equation modeling (1)
- multiplexed immunofluorescence (1)
- multivariate mixed model (1)
- myositis (1)
- nanocrystalline materials (1)
- nanoparticle growth (1)
- nanoscience (1)
- nanostructure (1)
- natural products (1)
- neoadjuvant chemoradiotherapy (1)
- nerve-sparing (1)
- neuroblastoma (1)
- neurovascular bundle preservation (1)
- nitro-fatty acids (1)
- nodular lymphocyte-predominant Hodgkin lymphoma (1)
- non-small-cell lung cancer (1)
- nonstructural proteins (1)
- nutrition - clinical (1)
- optical coherence tomography (1)
- oral cavity cancer (1)
- organic thin films (1)
- p53 activator (1)
- palmitoylation (1)
- pediatric intensive care (1)
- penile cancer (1)
- peri-implantitis (1)
- perioperative outcome (1)
- personality (1)
- pharmacoresistance (1)
- phylogenetic community distance (1)
- polytypism (1)
- predictive biomarker (1)
- prognosis (1)
- progressive myoclonus epilepsy (1)
- prostate neoplasm (1)
- prostate volume (1)
- prostate-specific antigen (1)
- proteins (1)
- proteobacteria (1)
- proteomics (1)
- pseudomonas aeruginosa (1)
- pulmonary failure (1)
- quark gluon plasma (1)
- radiation (1)
- radical prostatecomy (1)
- radiotherapy (1)
- randomized (1)
- re-exposure (1)
- reactive oxygen species (1)
- rechallenge (1)
- reintroduction (1)
- repeat biopsy (1)
- repeatability (1)
- reproducibility (1)
- resilience (1)
- respiratory failure (1)
- rigor (1)
- risk factors (1)
- risk stratification (1)
- robust test statistic (1)
- satellite telemetry (1)
- schizophrenia (1)
- secondary data analysis (1)
- selenolates (1)
- self-assembled monolayers (1)
- sepsis (1)
- simplified production (1)
- single subject classification (1)
- smart home (1)
- smart living (1)
- spectra (1)
- stage-based models (1)
- standardization (1)
- structural proteins (1)
- strumpellin (1)
- stuttering (1)
- subgrouping (1)
- surface chemistry (1)
- surface-mounted metal–organic frameworks (SURMOFs) (1)
- surgical margin (1)
- survivin (1)
- sustainable travel (1)
- targeted biopsy (1)
- temozolomide (1)
- temporal classification (1)
- thiolates (1)
- transrectal prostate biopsy (1)
- trauma (1)
- travel behavior change (1)
- treatment centres (1)
- treatment resistance (1)
- triptycene (1)
- tropical forests (1)
- tumor microenvironment (1)
- tumor weight (1)
- tyrosine kinase inhibitor (TKI) (1)
- upgrading (1)
- uveal melanoma (1)
- ventral striatum (1)
- volatile organic compounds (1)
- waiting time (1)
- web of things (1)
- Öffentlichkeit (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1063)
- Frankfurt Institute for Advanced Studies (FIAS) (958)
- Informatik (926)
- Medizin (123)
- Geowissenschaften (42)
- Biowissenschaften (14)
- Biochemie, Chemie und Pharmazie (11)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (8)
- Geographie (7)
- Geowissenschaften / Geographie (7)
We discuss the prospects for parity-nonconservation experiments with highly charged heavy ions. Energy levels and parity mixing for heavy ions with 2–5 electrons are calculated. We investigate two-photon transitions and the possibility of observing interference effects between weak-matrix elements and Stark matrix elements for periodic electric field configurations.
This paper investigates the global stratospheric Brewer–Dobson circulation (BDC) in the ERA5 meteorological reanalysis from the European Centre for Medium-Range Weather Forecasts (ECMWF). The analysis is based on simulations of stratospheric mean age of air, including the full age spectrum, with the Lagrangian transport model CLaMS (Chemical Lagrangian Model of the Stratosphere), driven by reanalysis winds and total diabatic heating rates. ERA5-based results are compared to results based on the preceding ERA-Interim reanalysis. Our results show a significantly slower BDC for ERA5 than for ERA-Interim, manifesting in weaker diabatic heating rates and higher age of air. In the tropical lower stratosphere, heating rates are 30 %–40 % weaker in ERA5, likely correcting a bias in ERA-Interim. At 20 km and in the Northern Hemisphere (NH) stratosphere, ERA5 age values are around the upper margin of the uncertainty range from historical tracer observations, indicating a somewhat slow–biased BDC. The age trend in ERA5 over the 1989–2018 period is negative throughout the stratosphere, as climate models predict in response to global warming. However, the age decrease is not linear but steplike, potentially caused by multi-annual variability or changes in the observations included in the assimilation. During the 2002–2012 period, the ERA5 age shows a similar hemispheric dipole trend pattern as ERA-Interim, with age increasing in the NH and decreasing in the Southern Hemisphere (SH). Shifts in the age spectrum peak and residual circulation transit times indicate that reanalysis differences in age are likely caused by differences in the residual circulation. In particular, the shallow BDC branch accelerates in both reanalyses, whereas the deep branch accelerates in ERA5 and decelerates in ERA-Interim.
Highlights
• Explanation of mobility design and its practical, aesthetic and emblematic effects on travel behaviour.
• Review of recent studies on mobility design elements and the promotion of non-motorised travel.
• Discussion of research gaps and methodological challenges of data collection and comparability.
Abstract
To promote non-motorised travel, many travel behaviour studies acknowledge the importance of the built environment to modal choice, for example with its density or mix of uses. From a mobility design theory perspective, however, objects and environments affect human perceptions, assessments and behaviour in at least three different ways: by their practical, aesthetic and emblematic functions. This review of existing evidence will argue that travel behaviour research has so far mainly focused on the practical function of the built environment. For that purpose, we systematically identified 56 relevant studies on the impacts of the built environment on non-motorised travel behaviour in the Web of Science database. The focus of research on the practical design function primary involves land use distribution, street network connectivity and the presence of walking and cycling facilities. Only a small number of papers address the aesthetic and emblematic functions. These show that the perceived attractiveness of an environment and evoked feelings of traffic safety increase the likelihood of walking and cycling. However, from a mobility design perspective, the results of the review indicate a gap regarding comprehensive research on the effects of the aesthetic and emblematic functions of the built environment. Further research involving these functions might contribute to a better understanding of how to promote non-motorised travel more effectively. Moreover, limitations related to survey techniques, regional distribution and the comparability of results were identified.
Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany
(2012)
Objectives: This summary evaluates the outcomes of orthotopic liver transplantation (OLT) of HIV-positive patients in Germany.
Methods: Retrospective chart analysis of HIV-positive patients, who had been liver-transplanted in Germany between July 1997 and July 2011.
Results: 38 transplantations were performed in 32 patients at 9 German transplant centres. The reasons for OLT were end-stage liver disease (ESLD) and/or liver failure due to hepatitis C (HCV) (n = 19), hepatitis B (HBV) (n = 10), multiple viral infections of the liver (n = 2) and Budd-Chiari-Syndrome. In July 2011 19/32 (60%) of the transplanted patients were still alive with a median survival of 61 months (IQR (interquartile range): 41-86 months). 6 patients had died in the early post-transplantation period from septicaemia (n = 4), primary graft dysfunction (n = 1), and intrathoracal hemorrhage (n = 1). Later on 7 patients had died from septicaemia (n = 2), delayed graft failure (n = 2), recurrent HCC (n = 2), and renal failure (n = 1). Recurrent HBV infection was efficiently prevented in 11/12 patients; HCV reinfection occurred in all patients and contributed considerably to the overall mortality.
Conclusions: Overall OLT is a feasible approach in HIV-infected patients with acceptable survival rates in Germany. Reinfection with HCV still remains a major clinical challenge in HIV/HCV coinfection after OLT.
In resource-limited or point-of-care settings, rapid diagnostic tests (RDTs), that aim to simultaneously detect HIV antibodies and p24 capsid (p24CA) antigen with high sensitivity, can pose important alternatives to screen for early infections. We evaluated the performance of the antibody and antigen components of the old and novel version of the Determine™ HIV-1/2 Ag/Ab Combo RDTs in parallel to quantifications in a fourth-generation antigen/antibody immunoassay (4G-EIA), p24CA antigen immunoassay (p24CA-EIA), immunoblots, and nucleic acid quantification. We included plasma samples of acute, treatment-naïve HIV-1 infections (Fiebig stages I–VI, subtypes A1, B, C, F, CRF02_AG, CRF02_AE, URF) or chronic HIV-1 and HIV-2 infections. The tests’ antigen component was evaluated also for a panel of subtype B HIV-1 transmitted/founder (T/F) viruses, HIV-2 strains and HIV-2 primary isolates. Furthermore, we assessed the analytical sensitivity of the RDTs to detect p24CA using a highly purified HIV-1NL4-3 p24CA standard. We found that 77% of plasma samples from acutely infected, immunoblot-negative HIV-1 patients in Fiebig stages II–III were identified by the new RDT, while only 25% scored positive in the old RDT. Both RDTs reacted to all samples from chronically HIV-1-infected and acutely HIV-1-infected patients with positive immunoblots. All specimens from chronically infected HIV-2 patients scored positive in the new RDT. Of note, the sensitivity of the RDTs to detect recombinant p24CA from a subtype B virus ranged between 50 and 200 pg/mL, mirrored also by the detection of HIV-1 T/F viruses only at antigen concentrations tenfold higher than suggested by the manufacturer. The RTD failed to recognize any of the HIV-2 viruses tested. Our results indicate that the new version of the Determine™ HIV-1/2 Ag/Ab Combo displays an increased sensitivity to detect HIV-1 p24CA-positive, immunoblot-negative plasma samples compared to the precursor version. The sensitivity of 4G-EIA and p24CA-EIA to detect the major structural HIV antigen, and thus to diagnose acute infections prior to seroconversion, is still superior.
Simple Summary: Penile cancer is a rare but aggressive malignancy characterized by rapid tumor growth as well as prompt metastasis in groin lymphatics. While localized diseases can be successfully cured by surgery in most cases, no truly effective treatment options have been established for metastatic diseases as of yet. In the current investigation, we assessed the value of selected members of the PI3K/mTOR/AKT pathway to serve as tumor markers or therapeutic targets for this disease. Higher expression of AKT was significantly more prevalent in high-grade tumors and independently predictive of the worse survival parameters, while increased expression of pmTOR was associated with an inferior prognosis as well. Treatment with the pan-AKT inhibitor capivasertib in PeCa cell lines induced significant reduction of cell viability and movement capacity. These findings might aid in the understanding of the molecular tumor background as well as development of novel treatment options for advanced penile cancer.
Abstract: The PI3K/mTOR/AKT pathway might represent an intriguing option for treatment of penile cancer (PeCa). We aimed to assess whether members of this pathway might serve as biomarkers and targets for systemic therapy. Tissue of primary cancer from treatment-naïve PeCa patients was used for tissue microarray analysis. Immunohistochemical staining was performed with antibodies against AKT, pAKT, mTOR, pmTOR, pS6, pPRAS, p4EBP1, S6K1 and pp70S6K. Protein expression was correlated with clinicopathological characteristics as well as overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS) and metastasis-free survival (MFS). AKT inhibition was tested in two primarily established, treatment-naïve PeCa cell lines by treatment with capivasertib and analysis of cell viability and chemotaxis. A total of 76 patients surgically treated for invasive PeCa were included. Higher expression of AKT was significantly more prevalent in high-grade tumors and predictive of DSS and OS in the Kaplan–Meier analysis, and an independent predictor of worse OS and DSS in the multivariate regression analysis. Treatment with pan-AKT inhibitor capivasertib in PeCa cell lines induced a significant downregulation of both total AKT and pAKT as well as decreased cell viability and chemotaxis. Selected protein candidates of the mTOR/AKT signaling pathway demonstrate association with histological and survival parameters of PeCa patients, whereas AKT appears to be the most promising one.
Purpose: Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa.
Materials and methods: Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested.
Results: The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading.
Conclusion: Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker.
Purpose: Monocentric, prospective study to investigate whether concomitant support of cochlear implant (CI) patients by CI-trained otolaryngologists and application of a standardized head bandage can minimize potential complications during magnetic resonance imaging (MRI).
Methods: Thirty-seven patients with 46 CIs underwent MRI with a prophylactic head bandage. All participants and the otolaryngologist at the CI center completed pre- and post-MRI questionnaires documenting body region scanned, duration of MRI and bandage wear, field strength during the scan, and any complications. If pain was experienced, it was assessed using a visual analog scale (1–10).
Results: MRI was performed without adverse events in 37.8% of cases. Magnet dislocation requiring surgical revision occurred in 2% of cases. Pain was reported in 86% of cases, often due to the tightness of the dressing. Patients with rotating, MRI-compatible magnets reported significantly less pain than participants with older-generation implants. In 11% of cases, the MRI was discontinued.
Conclusion: Serious complications during MRI in cochlear implant patients are rare. Pain is the most common adverse event, probably mainly due to the tight bandage required by most implant types. With newer generations of magnets, these patients experience less pain, no dislocation of the magnets, and no need for bandaging. Although magnet dislocation cannot be completely prevented in older generations of implants, it appears to be reduced by good patient management, which recommends examination under the guidance of physicians trained in the use of hearing implants.
Background: Radiofrequency ablation is a minimal invasive therapy in the treatment of bone metastases. In this study we present a new ablation system enabling an ablation in multiple directions and with an adaptable size and shape.
Material and methods: VX-2 tumor was used for the induction of experimental bone metastases in the femur of six New Zealand white rabbits. X-ray imaging as well as CT and MRI scans before and after treatment was carried out. After detecting bone tumor, radiofrequency ablation was performed. The ablation instrument contained a 10 g bipolar, articulated extendable electrode and a proprietary generator with an impedance controlled algorithm. All bones and the soft tissue were examined histologically.
Results: All animals developed local bone tumor. Mean duration until first osteolytic lesions on CT-scans was 48±14 days. The mean lesion area was 26 mm(2). No systemic tumor spread was seen. 6 radiofrequency procedures were carried out with a mean application time of 6 min±2:30 and an average temperature in the region of effect of 55 °C±4. MRI imaging demonstrated an ablation zone of 23±6 mm around the electrode. Histopathology showed an extensive heat necrosis with no remaining tumor cells in the ablation area.
Conclusion: Radiofrequency ablation is a quickly developing treatment option on the field of minimal invasive bone tumor therapy. The electrode enables an ablation adapted to size and shape of the metastases. Further clinical studies are necessary to test and enhance this radiofrequency system.
Using the notion of a root datum of a reductive group G we propose a tropical analogue of a principal G-bundle on a metric graph. We focus on the case G=GLn, i.e. the case of vector bundles. Here we give a characterization of vector bundles in terms of multidivisors and use this description to prove analogues of the Weil--Riemann--Roch theorem and the Narasimhan--Seshadri correspondence. We proceed by studying the process of tropicalization. In particular, we show that the non-Archimedean skeleton of the moduli space of semistable vector bundles on a Tate curve is isomorphic to a certain component of the moduli space of semistable tropical vector bundles on its dual metric graph.
Der Vorstand der Deutschen Gesellschaft für Epileptologie und die Kommission „Epilepsie und Synkopen“ der Deutschen Gesellschaft für Neurologie haben die aktuelle Datenlage zur Impfung zur Vorbeugung der Corona-Virus-Krankheit 2019 (COVID-19) sowie zur Impfpriorisierung bei Menschen mit Epilepsie gesichtet, diese zusammengefasst und geben die unten genannten Empfehlungen ab.
Six p53 wild-type cancer cell lines from infrequently p53-mutated entities (neuroblastoma, rhabdomyosarcoma, and melanoma) were continuously exposed to increasing concentrations of the murine double minute 2 inhibitor nutlin-3, resulting in the emergence of nutlin-3-resistant, p53-mutated sublines displaying a multi-drug resistance phenotype. Only 2 out of 28 sublines adapted to various cytotoxic drugs harboured p53 mutations. Nutlin-3-adapted UKF-NB-3 cells (UKF-NB-3rNutlin10 μM, harbouring a G245C mutation) were also radiation resistant. Analysis of UKF-NB-3 and UKF-NB-3rNutlin10 μM cells by RNA interference experiments and lentiviral transduction of wild-type p53 into p53-mutated UKF-NB-3rNutlin10 μM cells revealed that the loss of p53 function contributes to the multi-drug resistance of UKF-NB-3rNutlin10 μM cells. Bioinformatics PANTHER pathway analysis based on microarray measurements of mRNA abundance indicated a substantial overlap in the signalling pathways differentially regulated between UKF-NB-3rNutlin10 μM and UKF-NB-3 and between UKF-NB-3 and its cisplatin-, doxorubicin-, or vincristine-resistant sublines. Repeated nutlin-3 adaptation of neuroblastoma cells resulted in sublines harbouring various p53 mutations with high frequency. A p53 wild-type single cell-derived UKF-NB-3 clone was adapted to nutlin-3 in independent experiments. Eight out of ten resulting sublines were p53-mutated harbouring six different p53 mutations. This indicates that nutlin-3 induces de novo p53 mutations not initially present in the original cell population. Therefore, nutlin-3-treated cancer patients should be carefully monitored for the emergence of p53-mutated, multi-drug-resistant cells.
Adaptation of wild-type p53 expressing UKF-NB-3 cancer cells to the murine double minute 2 inhibitor nutlin-3 causes de novo p53 mutations at high frequency (13/20) and multi-drug resistance. Here, we show that the same cells respond very differently when adapted to RITA, a drug that, like nutlin-3, also disrupts the p53/Mdm2 interaction. All of the 11 UKF-NB-3 sub-lines adapted to RITA that we established retained functional wild-type p53 although RITA induced a substantial p53 response. Moreover, all RITA-adapted cell lines remained sensitive to nutlin-3, whereas only five out of 10 nutlin-3-adapted cell lines retained their sensitivity to RITA. In addition, repeated adaptation of the RITA-adapted sub-line UKF-NB-3rRITA10 μM to nutlin-3 resulted in p53 mutations. The RITA-adapted UKF-NB-3 sub-lines displayed no or less pronounced resistance to vincristine, cisplatin, and irradiation than nutlin-3-adapted UKF-NB-3 sub-lines. Furthermore, adaptation to RITA was associated with fewer changes at the expression level of antiapoptotic factors than observed with adaptation to nutlin-3. Transcriptomic analyses indicated the RITA-adapted sub-lines to be more similar at the gene expression level to the parental UKF-NB-3 cells than nutlin-3-adapted UKF-NB-3 sub-lines, which correlates with the observed chemotherapy and irradiation sensitivity phenotypes. In conclusion, RITA-adapted cells retain functional p53, remain sensitive to nutlin-3, and display a less pronounced resistance phenotype than nutlin-3-adapted cells.
Investigators in the cognitive neurosciences have turned to Big Data to address persistent replication and reliability issues by increasing sample sizes, statistical power, and representativeness of data. While there is tremendous potential to advance science through open data sharing, these efforts unveil a host of new questions about how to integrate data arising from distinct sources and instruments. We focus on the most frequently assessed area of cognition - memory testing - and demonstrate a process for reliable data harmonization across three common measures. We aggregated raw data from 53 studies from around the world which measured at least one of three distinct verbal learning tasks, totaling N = 10,505 healthy and brain-injured individuals. A mega analysis was conducted using empirical bayes harmonization to isolate and remove site effects, followed by linear models which adjusted for common covariates. After corrections, a continuous item response theory (IRT) model estimated each individual subject’s latent verbal learning ability while accounting for item difficulties. Harmonization significantly reduced inter-site variance by 37% while preserving covariate effects. The effects of age, sex, and education on scores were found to be highly consistent across memory tests. IRT methods for equating scores across AVLTs agreed with held-out data of dually-administered tests, and these tools are made available for free online. This work demonstrates that large-scale data sharing and harmonization initiatives can offer opportunities to address reproducibility and integration challenges across the behavioral sciences.
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Ependymomas encompass a heterogeneous group of central nervous system (CNS) neoplasms that occur along the entire neuroaxis. In recent years, extensive (epi-)genomic profiling efforts have identified several molecular groups of ependymoma that are characterized by distinct molecular alterations and/or patterns. Based on unsupervised visualization of a large cohort of genome-wide DNA methylation data, we identified a highly distinct group of pediatric-type tumors (n = 40) forming a cluster separate from all established CNS tumor types, of which a high proportion were histopathologically diagnosed as ependymoma. RNA sequencing revealed recurrent fusions involving the pleomorphic adenoma gene-like 1 (PLAGL1) gene in 19 of 20 of the samples analyzed, with the most common fusion being EWSR1:PLAGL1 (n = 13). Five tumors showed a PLAGL1:FOXO1 fusion and one a PLAGL1:EP300 fusion. High transcript levels of PLAGL1 were noted in these tumors, with concurrent overexpression of the imprinted genes H19 and IGF2, which are regulated by PLAGL1. Histopathological review of cases with sufficient material (n = 16) demonstrated a broad morphological spectrum of tumors with predominant ependymoma-like features. Immunohistochemically, tumors were GFAP positive and OLIG2- and SOX10 negative. In 3/16 of the cases, a dot-like positivity for EMA was detected. All tumors in our series were located in the supratentorial compartment. Median age of the patients at the time of diagnosis was 6.2 years. Median progression-free survival was 35 months (for 11 patients with data available). In summary, our findings suggest the existence of a novel group of supratentorial neuroepithelial tumors that are characterized by recurrent PLAGL1 fusions and enriched for pediatric patients.
Chemotherapy and diffuse low-grade gliomas : a survey within the European Low-Grade Glioma Network
(2018)
Background: Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial.
Methods: An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients.
Results: The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression.
Conclusions: The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.
Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR–ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 106, 1.08±0.11 × 105, 1.03±0.10 × 104, 1.02±0.09 × 103, 1.04±0.10 × 102 and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR–ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR–ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).
The multistep PROTAC (PROteolysis TArgeting Chimeras) degradation process poses challenges for their rational development, as rate limiting steps determining PROTAC efficiency remain largely unknown. Moreover, the slow throughput of currently used endpoint assays does not allow the comprehensive analysis of larger series of PROTACs. Here we developed cell-based assays using NanoLuciferase and HaloTags, that allow measuring PROTAC induced degradation and ternary complex formation kinetics and stability in cells. Using PROTACs developed for degradation of WDR5, the characterization of the mode of action of these PROTACs in the early degradation cascade revealed a key role of ternary complex formation and stability. Comparing a series of ternary complex crystal structures highlighted the importance of an efficient E3-target interface for ternary complex stability. The developed assays outline a strategy for the rational optimization of PROTACs using a series of live cell assays monitoring key steps of the early PROTAC induced degradation pathway.
Significance The multistep PROTAC induced degradation process of a POI poses a significant challenge for the rational design of these bifunctional small molecules as critical steps that limit PROTAC efficacy cannot be easily assayed at required throughput. In addition, the cellular location of the POI may pose additional challenges as some cellular compartments, such as the nucleus, may not be easily reached by PROTAC molecules and the targeted E3 ligases may not be present in this cellular compartment. We propose therefore a comprehensive assay panel for PROTACs evaluation in cellular environments using a sensor system that allows continuous monitoring of the protein levels of the endogenous POI. We developed a cell line expressing WDR5 from its endogenous locus in fusion with a small sequence tag (HiBIT) that can be reconstituted to functional NanoLuciferase (NLuc). This system allowed continuous monitoring of endogenous WDR5 levels in cells and together with HaloTag system also the continuous monitoring of ternary complex (E3, WDR5 and PROTAC) formation. As this assay can be run at high throughput, we used this versatile system monitoring three diverse chemical series of WDR5 PROTACs that markedly differ in their degradation properties. Monitoring cell penetration, binary complex formation (PROTAC-WDR5 and PROTAC-VHL) as well as ternary complex formation we found that PROTAC efficiency highly correlated with synergy of ternary complex formation in cells. This study represents a first data set on diverse PROTACs studying this property in cellulo and it outlines a strategy for the rational optimization of PROTACs. It also provided kinetic data on ternary complex assembly and dissociation that may serve as a benchmark for future studies utilizing also kinetic properties for PROTAC development. Comparative structural studies revealed larger PROTAC mediated interaction surfaces for PROTACs that efficiently formed ternary complexes highlighting the utility of structure based optimization of PROTAC induced ternary complexes in the development process.
Stimulation of renal collecting duct principal cells with antidiuretic hormone (arginine-vasopressin, AVP) results in inhibition of the small GTPase RhoA and the enrichment of the water channel aquaporin-2 (AQP2) in the plasma membrane. The membrane insertion facilitates water reabsorption from primary urine and fine-tuning of body water homeostasis. Rho guanine nucleotide exchange factors (GEFs) interact with RhoA, catalyze the exchange of GDP for GTP and thereby activate the GTPase. However, GEFs involved in the control of AQP2 in renal principal cells are unknown. The A-kinase anchoring protein, AKAP-Lbc, possesses GEF activity, specifically activates RhoA, and is expressed in primary renal inner medullary collecting duct principal (IMCD) cells. Through screening of 18,431 small molecules and synthesis of a focused library around one of the hits, we identified an inhibitor of the interaction of AKAP-Lbc and RhoA. This molecule, Scaff10-8, bound to RhoA, inhibited the AKAP-Lbc-mediated RhoA activation but did not interfere with RhoA activation through other GEFs or activities of other members of the Rho family of small GTPases, Rac1 and Cdc42. Scaff10-8 promoted the redistribution of AQP2 from intracellular vesicles to the periphery of IMCD cells. Thus, our data demonstrate an involvement of AKAP-Lbc-mediated RhoA activation in the control of AQP2 trafficking.